166 related articles for article (PubMed ID: 35867699)
1. Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Huygens S; Oude Munnink B; Gharbharan A; Koopmans M; Rijnders B
Clin Infect Dis; 2023 Feb; 76(3):e507-e509. PubMed ID: 35867699
[TBL] [Abstract][Full Text] [Related]
2. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.
Andrés C; González-Sánchez A; Jiménez M; Márquez-Algaba E; Piñana M; Fernández-Naval C; Esperalba J; Saubi N; Quer J; Rando-Segura A; Miarons M; Codina MG; Ruiz-Camps I; Pumarola T; Abrisqueta P; Antón A
Clin Microbiol Infect; 2023 Feb; 29(2):240-246. PubMed ID: 36067943
[TBL] [Abstract][Full Text] [Related]
4. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
[No Abstract] [Full Text] [Related]
5. Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS.
Adachi E; Saito M; Koga M; Tsutsumi T; Yotsuyanagi H
Intern Med; 2022 Nov; 61(22):3459-3462. PubMed ID: 36070950
[TBL] [Abstract][Full Text] [Related]
6. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.
Hirotsu Y; Kobayashi H; Kakizaki Y; Saito A; Tsutsui T; Kawaguchi M; Shimamura S; Hata K; Hanawa S; Toyama J; Miyashita Y; Omata M
Med; 2023 Nov; 4(11):813-824.e4. PubMed ID: 37683636
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study.
Malahe SRK; Hoek RAS; Dalm VASH; Broers AEC; den Hoed CM; Manintveld OC; Baan CC; van Deuzen CM; Papageorgiou G; Bax HI; Van Kampen JJ; Hellemons ME; Kho MML; de Vries RD; Molenkamp R; Reinders MEJ; Rijnders BJA
Clin Infect Dis; 2023 Feb; 76(3):e172-e178. PubMed ID: 35869843
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients.
Marques AD; Graham-Wooten J; Fitzgerald AS; Sobel Leonard A; Cook EJ; Everett JK; Rodino KG; Moncla LH; Kelly BJ; Collman RG; Bushman FD
mBio; 2024 Mar; 15(3):e0011024. PubMed ID: 38364100
[TBL] [Abstract][Full Text] [Related]
9. Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
Palomino-Cabrera R; Tejerina F; Molero-Salinas A; Ferris M; Veintimilla C; Catalán P; Rodríguez Macias G; Alonso R; Muñoz P; García de Viedma D; Pérez-Lago L;
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0026623. PubMed ID: 37278655
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
[TBL] [Abstract][Full Text] [Related]
11. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.
Rasmussen LD; Lebech AM; Øvrehus A; Poulsen BK; Christensen HR; Nielsen H; Johansen IS; Omland LH; Wiese L; Helleberg M; Storgaard M; Dalager-Pedersen M; Rasmussen TA; Benfield T; Petersen TS; Andersen ÅB; Gram MA; Stegger M; Edslev SM; Obel N
Br J Clin Pharmacol; 2023 Jun; 89(6):1820-1833. PubMed ID: 36519217
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
13. Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.
Cassin R; Rampi N; C F; Muscatello A; Mariani B; Noto A; Rossi FG; Baldini L
Hematol Oncol; 2023 Feb; 41(1):213-217. PubMed ID: 36156809
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Whole-Genome Sequence Characterization of a Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.5 Infection in an Immunocompromised Patient Successfully Treated With Sotrovimab 1000 mg.
Tejerina F; Palomino R; Catalan P; Sanz A; Marin M; Lopez-Andujar F; Perez L; Aldamiz T; Muñoz P; Rodriguez-Gonzalez C; Diez C; Fanciulli C; Lago LP; de Viedma DG
Clin Infect Dis; 2023 May; 76(10):1872-1874. PubMed ID: 36799435
[No Abstract] [Full Text] [Related]
16. Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts.
Nevejan L; Ombelet S; Laenen L; Keyaerts E; Demuyser T; Seyler L; Soetens O; Van Nedervelde E; Naesens R; Geysels D; Verstrepen W; Cattoir L; Martens S; Michel C; Mathieu E; Reynders M; Evenepoel A; Hellemans J; Vanhee M; Magerman K; Maes J; Matheeussen V; Boogaerts H; Lagrou K; Cuypers L; André E
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560741
[TBL] [Abstract][Full Text] [Related]
17. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
18. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.
Destras G; Bal A; Simon B; Lina B; Josset L
Lancet Microbe; 2022 Aug; 3(8):e559. PubMed ID: 35636438
[No Abstract] [Full Text] [Related]
19. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
